NASP inSPire

Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

At inSPire2026, experts highlighted gaps in specialty therapy payment, 340B data, clinical trials, and AI-driven care.

Pharmacy leaders examined AI for authorizations, adherence, patient access, and efficient specialty pharmacy benefits in health-system care.

Chester Good, MD, MPH, shares data and strategies used by UPMC to evaluate value-based contracting in specialty pharmacy.

Two posters report 3.9% first-year GLP-1 discontinuation and a 5-day median time to first fill under pharmacist-led care.

Sophy Levine, PharmD, discusses how an integrated health system specialty pharmacy may help lower 1-year GLP-1 discontinuation.

Panelists say IRA, Most Favored Nation rules and fragmented data are freezing value-based deals for durable one-time therapies.

At NASP's inSPire2026, covered entities and manufacturers debate 340B program reform, contract pharmacies, and the 2027 rebate model.

Irfana Lakada, PharmD, CSP, explains why onboarding may be the wrong time to screen for social needs and why rescreening matters.

Jesse Dresser explains how federal PBM reform, a new CMS RFI, and FTC settlements could reshape specialty pharmacy contracts and pay from 2027.

Switching MS patients to subcutaneous ocrelizumab cut chair time 82.8% and delivered $514,544 in 3-year value, a UVA analysis finds.

A narrative review finds specialty pharmacies lack a patient-reported outcome measure built for their workflow, despite frequent contact with patients with MS.

Panelists at NASP inSPire2026 said specialty pharmacies could close clinical trial enrollment gaps by capturing one missed data point.

Medicare's cell and gene therapy payment gap remains, with hospitals absorbing costs as insurers limit coverage.

Geeta Nayyar, MD, MBA, says AI's real health care payoff is cutting administrative friction with clean data and clinical leadership.

Specialty pharmacy leaders will gather in National Harbor for inSPire2026, tackling cell and gene therapy access, AI, and high-cost drug pricing.